Pumis Biotechnology (Zhuhai) Co., Ltd.

MAINZ, Germany, October 21, 2024 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will announce its financial results for the third quarter 2024 on Monday, November 4, 2024. Additionally, the Company will host a conference call and webcast that day at 8:00 a.m. ET (2:00 p.m. CET) for investors, financial analysts and the general public to discuss its financial results and provide a corporate update. To access the live conference call via telephone, please register via this link. Once registered, dial-in numbers and a PIN will be provided. It is recommended to register at least one day in advance. The slide presentation and audio of the webcast will be available via this link. Participants may also access the slides and the webcast of the conference call via the “Events & Presentations” page in the Investor Relations section of the Company’s website at www.BioNTech.com. A replay of the webcast will be made available shortly after the call and archived on the Company’s website for 30 days following the call. About BioNTech Biopharmaceutical New Technologies (BioNTech) is a global next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. BioNTech exploits a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals. Its broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor (CAR) T cells, several protein-based therapeutics, including bispecific immune checkpoint modulators, targeted cancer antibodies and antibody-drug conjugate (ADC) therapeutics, as well as small molecules. Based on its deep expertise in mRNA vaccine development and in-house manufacturing capabilities, BioNTech and its collaborators are developing multiple mRNA vaccine candidates for a range of infectious diseases alongside its diverse oncology pipeline. BioNTech has established a broad set of relationships with multiple global and specialized pharmaceutical collaborators, including Biotheus, DualityBio, Fosun Pharma, Genentech, a member of the Roche Group, Genevant, Genmab, MediLink, OncoC4, Pfizer and Regeneron. For more information, please visit www.BioNTech.com. CONTACTS Investor RelationsMichael HorowiczInvestors@biontech.de Media RelationsJasmina Alatovic+49 (0)6131 9084 1513Media@biontech.de

The agreement focuses on advancing Talem Therapeutics’ lead bispecific antibody, TATX-20, for treating hypoxic solid tumours. Credit: Sebastian Kaulitzki via Shutterstock. ImmunoPrecise Antibodies, an AI-driven biotherapeutic research and technology company, has entered into a material transfer and evaluation agreement (MTEA) with Biotheus on bispecific antibodies to treat cancer. The agreement focuses on the development of a new bispecific antibody therapy targeting hypoxic solid tumours using Talem Therapeutics’ TATX-20 lead candidate. Under the MTEA, Biotheus will receive the specialised antibody asset from Talem Therapeutics, a subsidiary of ImmunoPrecise Antibodies and plans to utilise it alongside its proprietary technology to create new drugs for cancer. These therapeutics aim to simultaneously target two different tumour markers, offering a potential breakthrough in cancer treatment, especially for tumours in oxygen-deprived environments. Biotheus co-founder, chair, and CEO Xiaolin Liu said: “We are happy to enter into a collaboration with ImmunoPrecise Antibodies, a leading AI-driven biotech with powerful multi-omics modelling expertise. See Also: Cloud Computing in the Pharmaceutical Industry Retail Pharmacies for the Pharmaceutical Industry “Biotheus’ broad expertise in antibody discovery and development is powered by our fully integrated capabilities. By virtue of the AI-informed molecules spawned by ImmunoPrecise’s platform, we aim to develop novel bispecific antibodies with first-in-class potential and bring forth breakthrough therapies to cancer patients in the world.” The collaboration seeks to expedite the development of targeted therapies that could enhance patient outcomes for those with solid tumours. Biotheus will assess the TATX-20 candidate, and upon successful evaluation, will advance the development of bispecific molecules. The goal is to produce a clinically effective product that can overcome the resistance of hypoxic solid tumours to existing treatments. ImmunoPrecise Antibodies CEO Dr Jennifer Bath said: “Our collaboration aims to accelerate the creation of innovative cancer treatments, potentially leading to groundbreaking clinical outcomes. “This agreement not only demonstrates the value of our AI-enhanced assets but also sets the stage for a long-term, mutually beneficial partnership that could transform the landscape of cancer therapeutics. We anticipate this collaboration will drive significant value for both companies and, most importantly, for patients in need of advanced treatment options.” Biotheus announced an expansion of its strategic partnership with Hansoh Pharmaceutical Group in March 2024. This expansion pertains to the development of bispecific antibody-drug conjugates targeting EGFR/cMET, marking a significant step forward in the company’s oncology and inflammatory disease portfolio.

The dark matter of the genome is the majority of the human genome, making up around 98% of it. Image credit: Shutterstock/ Tartila. Enara Bio has raised $32.5m in a Series B financing round to advance its platform shining a light on cancer-specific antigens from previously uncharted genomic dark matter. The round was led by Pfizer ’s and Merck KGaA’s respective investment arms, who joined as new backers. The Francis Crick Institute also joined the round as a new investor, alongside original backers including RA Capital, Samsara BioCapital and SV Health Investors, as per a 3 October press release. UK-based Enara said the funds will be used to develop its pipeline of T cell receptor (TCR)-based therapies that target regions of the genome considered ‘dark’ or non-coding. As far as scientists know, these areas of the genome play no role normally in protein-coding. These areas are known as genomic dark matter and although usually silenced in healthy cells, they are often expressed in tumours following alterations to cellular processes. Enara states that cancer cells can therefore present novel peptide antigens on their surface, coded by these dark areas. The biotech attributes the name ‘Dark Antigens’ to these novel therapeutic targets it discovered. Enara’s EDAPT platform is what the company uses to discover and validate Dark Antigen targets for potential cancer immunotherapies. The platform combines bioinformatics databases with mass spectrometry of tumour and healthy tissues alongside RNA in situ hybridisation. See Also: ImmunoPrecise and Biotheus partner on bispecific antibodies to treat cancer Novaliq and Laboratoires Théa announce EC approval for dry eye disease therapy Whilst Enara has not shared details about its pipeline yet, the company said its “internal focus is developing TCR-directed immunotherapies against Dark Antigen targets that are highly prevalent and homogenously expressed across solid tumours.” Pfizer ventures partner Rana Al-Hallaq, who joins Enara’s board of directors following the financing, said: “Dark Antigens may unlock the potential of immunotherapy for many additional patients with solid tumours, and we are pleased to support Enara’s development of this cutting-edge platform to discover and validate these previously untapped targets.” Before Pfizer and Merck KGaA came on board, Enara had already attracted the interest of another big pharma. Boehringer Ingelheim licensed multiple Dark Antigens from the biotech to develop off-the-shelf immunotherapies for non-small cell lung cancer (NSCLC) in January this year as part of an ongoing collaboration originally started in 2021 . Boehringer did not disclose the upfront payment three years ago, but milestone and royalty payments could mean Enara is in line to receive $1.1bn from the partnership with the German drugmaker. Genomic dark matter has become a promising area for cancer detection, monitoring, and treatment. Earlier this year, researchers at Johns Hopkins University in the US used artificial intelligence (AI) to analyse these non-coding areas of genetic code found in tumours and the bloodstream. Enara is not the only biotech in the dark genome space – Rome Therapeutics has developed a candidate that targets the ‘jumping gene’ LINE-1 for the treatment of autoimmune conditions. The company raised $72m in a Series B round in September 2023, with backing from Johnson & Johnson (J&J) Innovation and Bristol Myers Squibb (BMS).